Introduction
Adamantane is an important moiety in many bioactive substances with a broad spectrum of biological activities. 1 Current approved therapeutic agents containing the adamantyl moiety range from remedies for Influenza A, Herpes simplex and Acne vulgaris to treatments for Parkinsonism, Alzheimer's disease and type II diabetes mellitus medicines (Vildaglitin, Saxagliptin) . Adamantane is also a common building block in new psychoactive substances (NPS), for example AKB-48, 5F-AKB-48, APICA and AB001. 2 Investigations regarding the metabolism of bioactive substances containing the adamantyl moiety have been extensively carried out.
3 Interestingly, most reports show that the tertiary carbons of the adamantyl moiety are much more prone to oxidation than the secondary carbons unless more than two tertiary carbons are already substituted. For example, 1-amino-3-hydroxyadamantane was the only detected metabolite of amantadine. 4 To the best of our knowledge, there are no reports regarding adamantane containing bioactive substances that exclusively produce a metabolite with a hydroxyl group on a secondary carbon of the adamantyl moiety.
AKB-48, which contains the adamantane moiety, belongs to a family of synthetic cannabinoids that has gained increased popularity as a substitute to cannabis abuse in recent years. Challenges in detecting synthetic cannabinoids are largely due to their fast in vivo metabolism, together with a lack of knowledge concerning their metabolism. The limited access to reference substances and optimized detection methods for these substances in urine are also of concern. Several studies have been conducted on the metabolism of AKB-48 using LC-QTOF-MS to analyse the culture media of human liver microsomes or hepatocytes. The metabolite with a single hydroxyl group on the adamantyl moiety was found to be a major metabolite with an ambiguous structure ( Fig. 1) , 5 making it a good candidate for use as a biomarker for AKB-48 intake. This necessitated identification of the exact position of the hydroxyl group, requiring the synthesis of relevant reference substances. Although isolation and identification of metabolites present in urine samples would also work, such an approach is less appropriate as it requires large quantities of samples and extensive animal experiments.
3 This makes the synthesis of metabolites more applicable in the battle against the rapidly growing illegal drug market.
Results and discussion
Adamantine 1 was oxidized using concentrated H2SO4 and HNO3 at 10 °C to give 3-hydroxy-adamantine 2 in 74% yield, 6 which was coupled with 3-indazole-carboxylic acid to selectively form amide 3. 
Scheme 1. i) conc. H2SO4, conc. HNO3, 2 h at 10 °C, 74%; ii) TBTU, 1H-indazole-3-carboxylic acid, Et3N, THF, rt, overnight, 81%; iii) 1-bromopentane, t-BuOK in THF/DMF (5:1), rt overnight, 90%.
Compound 4 was obtained after the alkylation of 3 with bromopentane in an overall yield of 54% (Scheme 1). According to the literature method, 7 the hydroxyl group of compound 5 was converted into an amine group via a Ritter reaction, followed by hydrolysis with HCl (aq) under microwave irradiation. The resulting crude product was coupled with 3-indazole-carboxylic acid to give compound 6. This ketone was alkylated and reduced to give two isomers, 8 and 9, in an overall yield of ̴ 8% and 4%, respectively, over five steps (Scheme 2). The yield of the final step was low due to the difficulty of separating the two isomers. Their structures were elucidated using 1D and 2D NMR (ESI). Scheme 2. i) CH3CN, BF3·Et2O, TFA; ii) conc. HCl (aq), 150 °C MW irradiation,1 h; iii) TBTU, 1H-indazole-3-carboxylic acid' Et3N, THF, rt, overnight, 30% over three steps; iv) 1-bromopentane, t-BuOK, DMF/THF (1:5), rt, overnight, 72%; v) NaBH4, 8, 36% and 9, 20%. The NPS are often screened using LC-HRMS in forensic toxicology laboratories. During routine LC methods applied at the National Board of Forensic Medicine (RMV), the three potential metabolites 4, 8 and 9 co-eluted. A structured method development process was successfully applied to establish an LC method, enabling the separation of these compounds. In this method, an LC gradient from 26 to 67% MeCN in 10 mM ammonium acetate on a 100x2.1 mm Cortecs UPLC C18 column (Waters) over 7.5 min was applied. Using this method, compound 8 was found to be the target metabolite (Fig. 2) , which can be used as a biomarker for detection of AKB-48 in urine sample.
Conclusion
In conclusion, we report the straightforward synthesis and identification of an important metabolite of AKB-48 with a single hydroxyl group on a secondary carbon of the adamantyl moiety. The presence of this metabolite in urine samples could therefore act as a biomarker to potentially reveal the abuse of AKB-48. The study also indicates another important, more general, metabolic picture of the adamantyl moiety, namely exclusive metabolism of the adamantyl moiety on a secondary carbon. Furthermore, these results highlight the importance of having access to all the potential metabolites. Without such a set of reference substances, it could be difficult to obtain accurate metabolism results of bioactive molecules containing the adamantyl moiety.
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General information
TLC was performed using 0.25 mm precoated silica-gel plates (Merck 60 F254), detection by UV-abs at 254 nm. Flash chromatography was performed using the following silica gel: High purity grade (Merck Grade 9385), pore size 60 Å, 230-240 mesh particle size. The reagents were purchased from Sigma-Aldrich and Fluka (TBTU and BF3(OEt)2). The results of the high-resolution mass measurements using LC-QTOF-MS by National Board of Forensic Medicine, Sweden, can be found in the experimental.
3-Amino-1-adamantol (2) H 2 N OH
To a round bottom flask containing 1, amantadine hydrochloride (100 mg, 0.53 mmol) a mixture of concentrated sulfuric acid (2 ml, 37.1 mmol) and concentrated nitric acid (0.2 ml, 4.46 mmol) was added at 0 °C. The mixture was left to stir for two hours at 10 °C. Ice-cold
S2
water was then carefully added to the reaction mixture, following this addition the reaction mixture was made basic using solid sodium hydroxide until precipitation could be seen. The solution was thereafter filtered and the wet solid collected and dissolved in DCM and left to stir for 30 minutes. Next, the solid was removed from the solution by filtration and washed with DCM. The DCM-solution containing 2 was concentrated to afford compound 2 (70 mg, yield 81% were added. The reaction mixture was left to stir overnight at room temperature. Concentrated and purified on silica using a mobile phase system of EtOAc/n-heptane (4:1) to give compound 3 (41.5 mg, yield 81%). Rf = 0.38 (4:1 EtOAc/n-heptane 143.0, 140.2, 127.9, 123.4, 122.8, 111.4 (aromatic C), 69.7 (HOC), 55.6, 55.5, 49.8, 49.7, 44.9, 41.4, 36.1, 32.2 (aliphatic C) .
(aliphatic C).

N-(3-hydroxyadamantan-1-yl)-1H-indazole-3-carboxamide (3)
N
N-(3-hydroxyadamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide (4)
N N O NH OH
S3
Compound 3 (32 mg, 0.10 mmol) was dissolved in DMF/THF (1:5, 7.2 ml) and left to stir at 0 °C. Following 5 minutes of stirring t-BuOK (17 mg, 0.15 mmol) was added and the solution was stirred for an additional 15 minutes. Finally 1-Bromopentane (13 µl, 0.10 mmol) was added to the solution, brought to room temperature and stirred overnight. The progression of the reaction was monitored by TLC. Water (30 ml) was added to the solution and extracted using EtOAc (3x20 ml). The combined organic phases were concentrated and the residue was purified on silica using an eluent composition of 2:1 EtOAc/n-heptane to afford compound 4 (35.4 mg, yield 90%). Rf = 0.44 (2:1 EtOAc/n-heptane 126.7, 123.1, 122.9, 122.5, 109.3 (aromatic C), 69.4 (COH), 54.4, 49.6, 49.5, 44.3, 40.7, 35.1, 30.9, 29.6, 29.0, 22.4, 14.1 (aliphatic C) . being let cool to room temperature and left overnight. The solvents were evaporated prior to the addition of a saturated NaHCO3(aq) solution (3 ml). Additional water was added and the solution was extracted using chloroform (3x20 ml). The organic phases were concentrated and the crude carboxamide was dissolved in concentrated HCl (3 ml). The solution was heated for one hour at 150 °C using microwave irradiation. The solvent was then evaporated. The crude 5-aminoadamantan-2-one was dissolved in THF (10 ml). 1 Indazole-3-carboxylic acid (32 mg, 0.2 mmol), TBTU (96 mg, 0.3 mmol) and Et3N (84 µl, 0.6 mmol) were added to the solution.
N-(4-oxoadamantan-1-yl)-1H-indazole-3-carboxamide (6)
The reaction mixture was left to stir overnight at room temperature. The solution was concentrated and purified on silica gel using a mobile phase system of EtOAc/n-heptane (4:1) to give 6 (27.8 mg, yield 30%). Rf = 0.57 (4:1 EtOAc/n-heptane mmol) was added and the solution was left to stir overnight. The progression of the reaction was monitored by TLC. Water (20 ml) was added to the solution which was extracted using EtOAc (3x20 ml). The combined organic phases were concentrated and the residue was purified on silica using an eluent composition of 1:1 EtOAc/n-heptane to afford compound 7 (24.6 mg, yield 72%). Rf = 0.53 (1:1 EtOAc/n-heptane (t, J = 6.9 Hz, 3H). 126.8, 123.0, 122.8, 122.7, 109.3 (aromatic C), 50.9, 49.5, 46.7, 42.3, 40.7, 38.5, 29.6, 29.0, 28.9, 22.4, 14.1 (aliphatic C) . 
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